financetom
Business
financetom
/
Business
/
MSCI Q1 profit jumps on higher demand for index products
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MSCI Q1 profit jumps on higher demand for index products
Apr 23, 2024 4:39 AM

April 23 (Reuters) - MSCI's ( MSCI ) first-quarter

profit rose on Tuesday, due to strong demand for its index

products and analytics services as the likelihood of fewer U.S.

Federal Reserve rate cuts sparked volatility.

Companies such as MSCI ( MSCI ) benefit from market swings as

investors rush to rebalance portfolios and hedge against risks.

Recurring subscriptions in its index segment -- agreements

where clients pay regular fees to access MSCI's ( MSCI ) products over a

specified period -- rose 8% to $213 million, primarily due to

strong growth from market-cap weighted and custom index products

and special packages.

Asset-based fees in the segment rose about 13% to $150.3

million.

"Record AUM balances in MSCI ( MSCI )-linked index products drove

strong revenue growth from asset-based fees," CEO Henry A.

Fernandez said.

The global index provider also offers clients subscriptions

for information, data and tools to help them evaluate and invest

in diverse global markets.

MSCI's ( MSCI ) ESG and climate arm posted a 16% jump in operating

revenue in the three months ended March 31.

Meanwhile, new recurring sales in analytics led to the

unit's highest first quarter in a decade with nearly 12% growth

in operating revenue.

Excluding one-off charges, MSCI ( MSCI ) earned $3.52 a share for the

first quarter, up from $3.14 a share a year earlier.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
Oct 11, 2024
07:41 AM EDT, 10/11/2024 (MT Newswires) -- Sagimet Biosciences ( SGMT ) said Friday that its experimental drug, denifanstat, used to treat certain metabolic-dysfunction-associated steatohepatitis patients, met its primary and secondary endpoints in a phase 2b study. The study showed that patients treated with the denifanstat showed statistically significant and clinically meaningful improvements in disease activity, MASH resolution, and fibrosis...
BRIEF-Vecima Acquires Falcon V Systems
BRIEF-Vecima Acquires Falcon V Systems
Oct 11, 2024
Oct 11 (Reuters) - Vecima Networks Inc ( VNWTF ): * VECIMA ACQUIRES FALCON V SYSTEMS, PROVIDER OF INNOVATIVE SOFTWARE ORCHESTRATION PLATFORM FOR CABLE, FIBER, AND MOBILE ACCESS NETWORKS * VECIMA NETWORKS ( VNWTF ): CHARTER COMMUNICATIONS WILL BE INITIAL CUSTOMER, SIGNING MULTI-YEAR DEAL TO DEPLOY BOTH PRINCIPAL CORE & TEST SUITE Source text for Eikon: Further company coverage: ...
CAMP4 Therapeutics Prices $75 Million IPO
CAMP4 Therapeutics Prices $75 Million IPO
Oct 11, 2024
07:33 AM EDT, 10/11/2024 (MT Newswires) -- CAMP4 Therapeutics said late Thursday it priced its initial public offering of about 6.8 million common shares at $11 per share for expected gross proceeds of about $75 million. Underwriters have been granted a 30-day option to buy up to about 1 million additional shares. Shares of the biotechnology company are expected to...
AGBA, Triller Complete All Steps for Merger, Awaiting Final Nasdaq Approval
AGBA, Triller Complete All Steps for Merger, Awaiting Final Nasdaq Approval
Oct 11, 2024
07:44 AM EDT, 10/11/2024 (MT Newswires) -- AGBA (AGBA) and Triller said Friday they have finalized all necessary steps for their upcoming merger, expected to be completed around Oct. 14, pending final Nasdaq approval. As part of the merger, AGBA will undergo a reverse stock split at a 4-to-1 ratio to comply with Nasdaq requirements. The reverse split will be...
Copyright 2023-2026 - www.financetom.com All Rights Reserved